Evidence map›Paper›PMID 38942806›Full record

ArticleCommunications biology2024

The origins of haplotype 58 (H58) Salmonella enterica serovar Typhi.

Megan E Carey, To Nguyen Thi Nguyen, Do Hoang Nhu Tran, Zoe A Dyson, Jacqueline A Keane, Duy Pham Thanh, Elli Mylona, Satheesh Nair, Marie Chattaway, Stephen Baker

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. A case for eliminating Widal testing for enteric fever, India.Bulletin of the World Health Organization · 2026
    Article
  4. Article
  5. Genomic analysis ofMicrobial genomics · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. ConfrontingInfection and drug resistance · 2026
    Review
  10. Article
  11. Article
  12. Article
  13. Laboratory epidemiology ofOne health (Amsterdam, Netherlands) · 2025
    Article
  14. Article
  15. Article
  16. Whole-genome sequencing for surveillance ofAfrican journal of laboratory medicine · 2025
    Article
  17. Emergence of carbapenem-resistantFrontiers in microbiology · 2025
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Megan E Carey *Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK. megan.carey@lshtm.ac.uk.ORCID 0000-0002-7797-9080
To Nguyen Thi Nguyen *The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Do Hoang Nhu TranSchool of Medicine, Stanford University, Stanford, CA, USA.ORCID 0009-0006-3316-4812
Zoe A DysonDepartment of Infection Biology, London School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0002-8887-3492
Jacqueline A KeaneCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK.ORCID 0000-0003-0739-6848
Duy Pham ThanhThe Hospital for Tropical Diseases, Wellcome Trust Major Overseas Program, Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.ORCID 0000-0001-7029-9210
Elli MylonaCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK.ORCID 0000-0002-2638-0713
Satheesh NairUnited Kingdom Health Security Agency, Gastrointestinal Bacteria Reference Unit, London, UK.ORCID 0000-0002-7297-1485
Marie ChattawayUnited Kingdom Health Security Agency, Gastrointestinal Bacteria Reference Unit, London, UK.ORCID 0000-0002-5288-9089
Stephen BakerCambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Department of Medicine, University of Cambridge, Cambridge, UK.

Funding

Wellcome Trust
6 · The paper itself

Abstract

Antimicrobial resistance (AMR) poses a serious threat to the clinical management of typhoid fever. AMR in Salmonella Typhi (S. Typhi) is commonly associated with the H58 lineage, a lineage that arose comparatively recently before becoming globally disseminated. To better understand when and how H58 emerged and became dominant, we performed detailed phylogenetic analyses on contemporary genome sequences from S. Typhi isolated in the period spanning the emergence. Our dataset, which contains the earliest described H58 S. Typhi organism, indicates that ancestral H58 organisms were already multi-drug resistant (MDR). These organisms emerged spontaneously in India in 1987 and became radially distributed throughout South Asia and then globally in the ensuing years. These early organisms were associated with a single long branch, possessing mutations associated with increased bile tolerance, suggesting that the first H58 organism was generated during chronic carriage. The subsequent use of fluoroquinolones led to several independent mutations in gyrA. The ability of H58 to acquire and maintain AMR genes continues to pose a threat, as extensively drug-resistant (XDR; MDR plus resistance to ciprofloxacin and third generation cephalosporins) variants, have emerged recently in this lineage. Understanding where and how H58 S. Typhi originated and became successful is key to understand how AMR drives successful lineages of bacterial pathogens. Additionally, these data can inform optimal targeting of typhoid conjugate vaccines (TCVs) for reducing the potential for emergence and the impact of new drug-resistant variants. Emphasis should also be placed upon the prospective identification and treatment of chronic carriers to prevent the emergence of new drug resistant variants with the ability to spread efficiently.

Indexed as

Anti-Bacterial AgentsPhylogenySalmonella typhiTyphoid FeverDrug Resistance, Multiple, BacterialGenome, BacterialHaplotypesHumansMutationAnti-Bacterial Agents

Identifiers

PMID38942806
PMCPMC11213900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.